Response to neoadjuvant chemotherapy in ICON8: A GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment
Andrew R. Clamp, Jonathan A. Ledermann(Cancer Institute (WIA)), Adrian Cook(University College London), Marcia Hall(Hillingdon Hospitals NHS Foundation Trust), Hani Gabra(Royal Children's Hospital), Timothy Perren(Royal Marsden NHS Foundation Trust), Ji‐Hoon Kim(Seoul National University), James D. Brenton(University of Cambridge), Andrew Dean, Richard Kaplan(University College London), Sudha Sundar(Sandwell & West Birmingham Hospitals NHS Trust), Sarah P. Blagden(Churchill Hospital), Elizabeth C James(MRC Clinical Trials Unit at UCL), Raj Naik(Queen Elizabeth Hospital), Iain A. McNeish(Beatson West of Scotland Cancer Centre), G. Dark(Freeman Hospital), Dearbhaile M. O’Donnell, Dolores Gallardo‐Rincón(Instituto Nacional de Cancerología), Jane Hook(University of Leeds), Rosemary Lord(Clatterbridge Cancer Centre NHS Foundation Trust)
Cited by 5
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k